As Mermaid Medical exhibits at CIRSE 2023, we show our commitment to engage in healthcare innovations. We envision a future where medical technology not only meets but exceeds expectations, providing healthcare professionals with the tools they need to enhance patient outcomes.
A Global Platform for Innovation
CIRSE, the Cardiovascular and Interventional Radiological Society of Europe, annually brings together medical professionals, researchers, and industry pioneers from around the world to exchange knowledge, collaborate, and explore the latest advancements in the field.
This year, Mermaid Medical proudly takes our place among these leaders, ready to unveil our cutting-edge products that exemplify excellence in medical technology.
The Star of the Show - A Fully Disposable System
The star of the show is the D*Clot® HD - a fully disposable system that is ready to use. No assembly required. It is indicated for mechanical declotting of AV dialysis fistulae and grafts. A unique feature for the D*Clot® HD is that it rotates at approximately 10,000RPM’s allowing for low torque.
The D*Clot® HD has already positioned itself as an essential tool for medical professionals seeking streamlined and effective solutions. At the heart of the D*Clot® HD's efficiency lies its active aspiration function, ingeniously integrated into a 6Fr catheter shaft. This negative pressure mechanism plays a pivotal role in thrombus maceration by drawing and securely holding thrombus near the rotating tip.
In a demonstration of its adaptability, the D*Clot® HD offers a reverse function that empowers medical professionals to navigate even in tight anatomical constraints. This functionality allows the tip to be carefully backed out of challenging areas, adding an extra layer of precision to every procedure.
Mermaid Medical is Excited to Showcase the Award-Winning Angel® Catheter
Another one of the spotlight innovations that we are excited to showcase is the award-winning Angel® Catheter. The Angel® Catheter is an IVC filter permanently attached to a triple lumen central venous catheter. The smart, elegant design of the Angel Catheter provides critical care physicians and their patients with prophylactic PE protection and guarantees IVC filter retrieval, a game changing promise that no other IVC filter can make.
As the first and only IVC filter to receive FDA clearance for a prophylactic use indication, the Angel® Catheter provides immediate and effective PE protection during a critical and frequently untreated window for critically ill patients.
Engagement and Collaboration
Mermaid Medical's participation at CIRSE 2023 goes beyond product exhibition - it is a celebration of collaboration and the spirit of innovation. We want to exchange knowledge, have insightful conversations, and network. Our experts are professionals in discussing the future of our medical technologies and how it can shape the course of patient care.
A Vision for the Future
As Mermaid Medical exhibits at CIRSE 2023, we show our commitment to engage in healthcare innovations. We envision a future where medical technology not only meets but exceeds expectations, providing healthcare professionals with the tools they need to enhance patient outcomes.
We are excited to meet you at CIRSE in September the 9-13, 2023 in The Bella Center in Copenhagen, Oerestad at Mermaid Medical’s booth: 36
Do you want to set up appointments in advance please contact us: https://www.mermaidmedical.com/contact-us/#tab--denmark
Mermaid Medical Group announces new exclusive distribution deal on the COBRA-OS® device for REBOA procedures from Front Line Medical Technologies Inc.
Mermaid Medical is proud to announce the appointment of Marcus Kildegaard Nielsen as the new global Sales Director, effective September 1st, 2024. Over the past six years, Marcus has made significant contributions in sales and marketing, bringing the right skills, ambitions, and mindset to ensure we keep driving the business forward.
Mermaid Medical proudly welcomes Daniel Nilsson Lennartz as the new Business Development Director, effective September 1st, 2024. As one of the co-founders, Daniel brings invaluable insights and expertise that will continue to drive the company’s growth and long-term success.